Practical Considerations for Detecting NTRK Gene Fusions

Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP

Video Categories: NTRK Gene Fusions

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, review molecular methodologies and factors to consider in the identification of TRK fusion–positive tumors.

November 10, 2012

PMO Interview with the Innovator Series: Volume 1

Deborah Dunsire, MD, President and CEO of Millennium: The Takeda Oncology Company, and Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation, discuss the issues and vision in improving personalized medicine strategies for patients with multiple myeloma.Deborah Dunsire, MD, is the former President and CEO of Millennium Pharmaceuticals, [ Read More ]

March 24, 2015

In Pursuit of Targeted Therapies

As we learn more about a person’s genetic makeup, the more we are able to target medicines to his/her needs and benefit. With continued research, Dr. Stainthorpe explains, we will be able to identify markers that allow us to target medicines more precisely to get better performance and reduce waste.